Hemab Therapeutics has highlighted new clinical and preclinical data across its coagulation disorders pipeline, including first-in-human results for HMB-002, new programme HMB-003, and long-term data for sutacimig.

Hemab Therapeutics has presented new clinical and preclinical findings across its haemostasis and coagulation pipeline at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, showcasing progress across three investigational programmes targeting severe bleeding disorders.

The company said the data reinforce momentum across its portfolio, which includes therapies in development for von Willebrand disease, Glanzmann thrombasthenia and other rare bleeding conditions with high unmet need.

The most advanced update came from HMB-002, a subcutaneous antibody in development for von Willebrand disease. First-in-human data from an ongoing Phase 1/2 study showed sustained elevation of von Willebrand factor and Factor VIII following dosing, supporting a non-replacement approach designed to increase endogenous clotting factors. No thromboembolic events were observed, and a multiple-dose evaluation is ongoing.

Hemab also introduced HMB-003, a preclinical long-acting peptide plasmin inhibitor designed as a novel antifibrinolytic therapy. The programme is intended to block fibrinolysis independently of the plasminogen activation pathway and has shown greater potency than tranexamic acid in preclinical models. First-in-human studies are planned for the second half of 2026, with potential applications across multiple bleeding indications including heavy menstrual bleeding.

For sutacimig, the company reported long-term extension data from a Phase 2 study in Glanzmann thrombasthenia showing sustained reductions in annualised treated bleeding rates and continued use in surgical settings. The programme has received FDA Breakthrough Therapy and EMA PRIME designations, with a Phase 3 trial planned for the second half of 2026.

Taken together, the updates reflect continued development across Hemab’s pipeline of therapies designed to address critical gaps in the treatment of rare coagulation disorders.

While the dataset spans multiple programmes and study types, Hemab said the findings collectively support ongoing clinical progression and further evaluation of its therapies in larger, controlled studies.

Benny Sørensen, chief executive officer of Hemab Therapeutics, said: “We’re advancing three programs with the potential to change that. We are progressing sutacimig to Phase 3 in GT, strengthening the clinical validation of HMB-002 in VWD, and introducing HMB-003, a novel long-acting peptide-based inhibitor of plasmin.”

He added that the company’s presentations at ISTH 2026 demonstrate continued momentum across its pipeline in rare bleeding disorders.